Dermatosis perforante por gefitinib

被引：8

作者：

Fernandez-Guarino, Montse ^{[1
]}

Aldanondo, Isabel ^{[1
]}

Gonzalez-Garcia, Carmen ^{[2
]}

Garrido, Pilar ^{[3
]}

Marquet, Ainhoa ^{[1
]}

Perez-Garcia, Bibiana ^{[1
]}

Jaen, Pedro ^{[1
]}

机构：

[1] Hosp Ramon & Cajal, Ser Dermatol, Madrid, Spain

[2] Hosp Ramon & Cajal, Serv Anat Patol, Madrid, Spain

[3] Hosp Ramon & Cajal, Serv Oncol, Madrid, Spain

来源：

ACTAS DERMO-SIFILIOGRAFICAS | 2006年 / 97卷 / 03期

关键词：

gefitinib; perforating dermatosis; epidermal growth receptor;

D O I：

10.1016/S0001-7310(06)73383-X

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Gefitinib (Iressa (R)) is a new antineoplastic agent that acts by selectively inhibiting epidermal growth factor receptor tyrosine kinase (EGFR-TK). It has shown activity against several solid tumors. Because of their action mechanism, gefitinib and other tyrosine kinase inhibitors have been associated with multiple cutaneous effects, most of which are mild and well tolerated. We present a case of perforating dermatosis after treatment with gefitinib.

引用

页码：208 / 211

页数：4

共 27 条

[1] Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition
Albanell, J
Rojo, F
Averbuch, S
Feyereislova, A
Mascaro, JM
Herbst, R
LoRusso, P
Rischin, D
Sauleda, S
Gee, J
Nicholson, RI
Baselga, J
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) : 110 - 124
[2] [Anonymous], 2004, BRIT J DERMATOL, V150, P238
[3] ZD1839 ('Iressa')1,2 as an anticancer agent
Baselga, J
Averbuch, SD
[J]. DRUGS, 2000, 60 (Suppl 1) : 33 - 40
[4] Baselga J, 2000, J CLIN ONCOL, V18, p54S
[5] KYRLES DISEASE .I. CLINICAL FINDINGS IN 5 CASES AND REVIEW OF LITERATURE
CARTER, VH
CONSTANTINE, VS
[J]. ARCHIVES OF DERMATOLOGY, 1968, 97 (06) : 624 - +
[6] Clinical Cancer Research, 2004, US FOOD DRUG ADM DRU, V10, P1212
[7] ACQUIRED REACTIVE PERFORATING COLLAGENOSIS - REPORT OF 6 CASES AND REVIEW OF THE LITERATURE
FAVER, IR
DAOUD, MS
SU, WPD
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1994, 30 (04) : 575 - 580
[8] Overview of the tolerability of gefitinib (IRESSA™) monotherapy -: Clinical experience in non-small-cell lung cancer
Forsythe, B
Faulkner, K
[J]. DRUG SAFETY, 2004, 27 (14) : 1081 - 1092
[9] Gee-Chen C, 2004, J CLIN ONCOL, V22, P4646
[10] Hansen LA, 1997, AM J PATHOL, V150, P1959

← 1 2 3 →